Post by account_disabled on Jan 1, 2024 5:32:19 GMT
Opens new perspectives for scientists on the natural functioning of cells. To speed up drug development Merck, a leading science and technology company Announced today that The company has entered into a licensing agreement with Promega Corp., a global manufacturer in the life sciences industry. Headquartered in Madison, Wisconsin, USA, the agreement gives the company access to Merck's underlying CRISPR intellectual property. Promega will use Merck's CRISPR gene-editing technology to Create research products and services Including in the area of drug development Udit Batra, Member of the Merck Executive Board and CEO of the Life Science business said, “With this license agreement, Promega intends to use our intellectual property. “The development of CRISPR-edited cell lines will play a key role in determining the efficacy, toxicity and other characteristics of drugs.” The agreement will give researchers a better read on the expression levels of physiological or natural proteins.
This will allow us to understand protein behavior more accurately. “This license takes the potential of CRISPR to the next level. And more importantly is giving scientists a new perspective on how cells naturally work,” said Bill Linton, President and CEO of Promega. “This is especially important in applied research in fields like cancer. and neuroscience" Promega is creating knock-in cell Telegram Number Data lines using CRISPR and is also available upon customer request. To respond to the needs of customers who are studying protein mechanics. Merck hopes to continue developing its CRISPR intellectual property portfolio with cutting-edge technologies such as paired Cas9 nickase, which reduces off-target effects, and proxy-CRISPR, which allows researchers to More options to accelerate drug development and access new ways to treat Merck currently holds 22 patents worldwide related to CRISPR technology, both method and composition. This includes CRISPR-Cas9-based technology for gene integration in mammalian cells.
As both a user and a provider of gene editing technology Merck supports genome-editing research under careful consideration of ethical and legal standards. The Company has established an independent, external Bioethics Advisory Panel. To determine the research guidelines in which the company's business is involved. This includes research involving or using genome editing. Merck has also clearly positioned itself on scientific and societal issues. To propose a treatment strategy that has the hope that it can be used in research and various applications. About Promega Promega Corporation is a leading provider of innovative solutions and technical support to the life sciences industry. The company's portfolio of approximately 4,000 products enables scientists around the world to advance their knowledge in genomics, proteomics, cell analysis, drug discovery and human testing. Founded in 1978, the company is headquartered in Madison, Wisconsin, with offices in 16 countries and more than 50 distributors worldwide.
This will allow us to understand protein behavior more accurately. “This license takes the potential of CRISPR to the next level. And more importantly is giving scientists a new perspective on how cells naturally work,” said Bill Linton, President and CEO of Promega. “This is especially important in applied research in fields like cancer. and neuroscience" Promega is creating knock-in cell Telegram Number Data lines using CRISPR and is also available upon customer request. To respond to the needs of customers who are studying protein mechanics. Merck hopes to continue developing its CRISPR intellectual property portfolio with cutting-edge technologies such as paired Cas9 nickase, which reduces off-target effects, and proxy-CRISPR, which allows researchers to More options to accelerate drug development and access new ways to treat Merck currently holds 22 patents worldwide related to CRISPR technology, both method and composition. This includes CRISPR-Cas9-based technology for gene integration in mammalian cells.
As both a user and a provider of gene editing technology Merck supports genome-editing research under careful consideration of ethical and legal standards. The Company has established an independent, external Bioethics Advisory Panel. To determine the research guidelines in which the company's business is involved. This includes research involving or using genome editing. Merck has also clearly positioned itself on scientific and societal issues. To propose a treatment strategy that has the hope that it can be used in research and various applications. About Promega Promega Corporation is a leading provider of innovative solutions and technical support to the life sciences industry. The company's portfolio of approximately 4,000 products enables scientists around the world to advance their knowledge in genomics, proteomics, cell analysis, drug discovery and human testing. Founded in 1978, the company is headquartered in Madison, Wisconsin, with offices in 16 countries and more than 50 distributors worldwide.